Connective Therapeutics, Genentech deal

Connective received exclusive U.S. development and marketing rights to GNE's Actimmune gamma interferon to treat dermatological diseases. GNE, which sells Actimmune to treat chronic granulomatous disease and is conducting Phase III trials in renal cell carcinoma, is licensing the product for indications outside the company's focus areas.

Connective plans to start Phase II/III trials with the product in atopic dermatitis in 1996, and plans a Phase II trial in keloids. ...